Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NUI1

UPID:
DECR2_HUMAN

ALTERNATIVE NAMES:
2,4-dienoyl-CoA reductase 2; Short chain dehydrogenase/reductase family 17C member 1

ALTERNATIVE UPACC:
Q9NUI1; Q6ZRS7; Q96ET0

BACKGROUND:
The enzyme Peroxisomal 2,4-dienoyl-CoA reductase, with alternative names such as 2,4-dienoyl-CoA reductase 2 and Short chain dehydrogenase/reductase family 17C member 1, is pivotal in peroxisomal degradation pathways. It efficiently catalyzes the NADP-dependent conversion of 2,4-dienoyl-CoA to trans-3-enoyl-CoA, a key step in the beta-oxidation of unsaturated fatty acids. Its ability to process a wide array of substrates, including very long-chain fatty acids, underscores its essential role in cellular lipid metabolism.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Peroxisomal 2,4-dienoyl-CoA reductase unveils potential avenues for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.